Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A New Efficient EBV AssociatedTechnologies of T Cells in Treating Malignant Tumors and Clinical Application

NCT02980315 is registered in ClinicalTrials.gov with The Second Hospital of Nanjing Medical University as lead sponsor.

NCT NCT02980315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02980315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A New Efficient EBV AssociatedTechnologies of T Cells in Treating Malignant Tumors and Clinical Application
Lead sponsor
The Second Hospital of Nanjing Medical University
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 30, 2016
Completion date
December 31, 2017
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal neoplasms